Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

22.91$0.40 1.78%
pre market       17:06:06 pm   

Stock Snapshot

22.51
Prev. Close
22.63
Open
880.43M
Market Cap
1.64M
Number of Shares
21.74
Day Low
23.02
Day High
22.91
-
P/E Ratio
20.53M
Free Float in %
-1.92
EPS 2021
1.42
Book Value per Share
1.99
Cash Flow per Share
BeyondSpring Inc. (BYSI)
BeyondSpring Inc. (BYSI) stock rallied over 1.78% intraday to trade at $22.91 share on NASDAQ. The stock opened with a gain of % at $22.63 and touched an intraday high of $23.02, rising 2.27% against the last close of $22.51. The stock went to a low of $21.74 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-17$23.05$22.51$23.27$21.861,034,770
2021-09-16$22.47$22.97$23.49$22.11702,609
2021-09-15$24.12$22.56$25.00$23.261,000,237
2021-09-14$24.12$23.43$25.00$23.261,067,668
2021-09-13$24.12$24.44$25.00$23.260
2021-09-10$24.12$24.44$25.00$23.26995,204
2021-09-03$27.62$26.84$28.37$26.55110,990,000
2021-09-02$28.71$28.05$28.87$27.54104,020,000
2021-09-01$31.68$28.48$31.70$28.03192,550,000
2021-08-31$27.66$31.31$33.00$27.66279,810,000
2021-08-30$28.40$27.59$29.33$26.83111,740,000
BeyondSpring Inc.
28 Liberty Street
39th Floor
New York, NY 10005
United States

http://www.beyondspringpharma.com
646 305 6387
Employees
61
Sector
Healthcare
Sales or Revenue
900000.00
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30

BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam